Featured content
How AI is changing the way therapeutic antibodies are designed
What if researchers could design therapeutic antibodies instead of relying on screening millions of candidates? Generative AI is making this increasingly possible, offering new ways to tackle challenging targets.
ArticleWhy reagent selection belongs inside assay design
High affinity is often a priority when selecting reagents, but does it guarantee better assay performance? Discover why binding kinetics and matrix selectivity matter when developing custom reagents for challenging targets.
ArticleVirtual cells vs experimental models: which can you trust?
How reliable are AI virtual cells compared with experimental models? We examine what each can predict or measure, the evidence behind their reliability and their role in early drug discovery.
ArticleThe next gene-editing breakthrough may start with the donor template
The editing machinery gets much of the attention in genome editing, but it’s the donor DNA template that can determine whether an edit works. Long synthetic ssDNA could offer researchers another option.
News
NewsMulti-lab study challenges reproducibility of psilocybin behavioural findings
A landmark multi-institution collaboration has found no reproducible lasting behavioural changes in mice 24 hours after a single psilocybin dose, raising important questions about research reproducibility in psychedelic drug discovery.
NewsNovel RNA-protein interactions reveal conserved SARS-CoV-2 antiviral targets
A new study has mapped previously unknown RNA-protein interactions across the SARS-CoV-2 genome, identifying conserved sites involving RdRp and the nucleocapsid protein as potential antiviral drug targets less susceptible to mutational escape.
NewsYAP/TAZ protein hyperactivity linked to immune evasion via PD-L2 upregulation
Researchers have identified a mechanism by which overactive YAP and TAZ proteins may simultaneously increase cancer cell visibility to the immune system and shield tumours from T-cell attack.
Newsp53 activation boosts T-cell potency against solid tumours
UCLA researchers have shown that transiently activating the tumour suppressor protein p53 using an investigational MDM2 inhibitor can reduce exhaustion in engineered T cells and significantly improve their ability to kill melanoma cells in vitro.
From our partners
Report
Lab Automation 2026: Inside the labs making drug discovery faster and more reliable
Six scientists and industry experts discuss the challenges of automating drug discovery, from improving screening reliability and reproducibility to developing more autonomous laboratories.
Webinar
From vial to viable: best practices for culturing organoids
Poor recovery, inconsistent growth and changes in morphology can affect organoid research. How much experimental variability starts with the culture itself?
Opinion and interviews
How multiomics can strengthen drug target discovery
How can multiomics help researchers identify more promising drug targets? Dr Shi-qi An explores how combining molecular data can reveal therapeutic vulnerabilities and mechanisms of drug resistance.
- Previous
- Next
Join now
Unlock exclusive industry insights
- Bookmark articles and resources to access anytime
- Enjoy free access to industry leading resources, webinars and insights
- Stay informed with the latest news and breakthroughs
- Receive updates and recommendations tailored to your research interests
Upcoming Webinars
Webinar
Cracking cell dynamics with single-cell proteomics and CRISPR
What can pooled CRISPR screening and protein‑level readouts reveal that transcriptomics alone can’t? Explore how single‑cell genomic perturbations, intracellular protein measurements and surface‑protein profiling expose signalling pathways and clarify antibody specificity.
Webinar
What it really takes to turn cancer discoveries into new therapies
Five leading cancer researchers from across genomics, proteomics, cell biology, chemical biology and gene therapy dig into what’s driving cancer drug discovery forward and what’s still holding progress back.
Webinar
Virus-like particles for vaccine serology: from dengue VLP production to neutralising antibody detection
Find out how virus-like particles are produced at scale, and how they can be used to measure IgM, IgG and neutralising antibody responses in vaccine development.
Webinar
From vial to viable: best practices for culturing organoids
Poor recovery, inconsistent growth and changes in morphology can affect organoid research. How much experimental variability starts with the culture itself?
Cracking cell dynamics with single-cell proteomics and CRISPR
What it really takes to turn cancer discoveries into new therapies
Virus-like particles for vaccine serology: from dengue VLP production to neutralising antibody detection
From vial to viable: best practices for culturing organoids
On-demand Webinars
- Previous
- Next
